Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $283,039.64 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64. Following the completion of the sale, the chief financial officer now directly owns 118,077 shares in the company, valued at approximately $2,885,801.88. This trade represents a 8.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98.

Hims & Hers Health Trading Up 6.1 %

Shares of HIMS opened at $27.81 on Thursday. The firm has a market cap of $6.08 billion, a PE ratio of 63.21 and a beta of 1.31. The company’s 50 day simple moving average is $27.42 and its 200-day simple moving average is $21.72. Hims & Hers Health, Inc. has a 12-month low of $8.14 and a 12-month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the firm posted ($0.04) EPS. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Finally, Piper Sandler raised their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Main Management ETF Advisors LLC purchased a new position in Hims & Hers Health in the 3rd quarter valued at $672,000. Robeco Institutional Asset Management B.V. purchased a new position in Hims & Hers Health in the 3rd quarter valued at $604,000. Carnegie Investment Counsel purchased a new position in Hims & Hers Health in the 3rd quarter valued at $5,531,000. Royce & Associates LP boosted its position in shares of Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Finally, Versor Investments LP purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth $634,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.